UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
| (Commission File Number) |
(IRS
Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On November 13, 2026, InspireMD, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “Offering”) of (i) 7,342,308 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and pre-funded warrants to purchase up to 50,350,000 shares of Common Stock (the “Pre-Funded Warrants”), and (ii) accompanying Series L warrants to purchase up to 43,269,231 shares of Common Stock (or, at the election of the holder, pre-funded warrants to purchase up to an equal number of shares of Common Stock in lieu thereof) (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants”), representing 75% of the aggregate number of Shares and Pre-Funded Warrants sold in the Offering. Each Share is being sold together with an accompanying Common Warrant at a combined public offering price of $0.65, and each Pre-Funded Warrant is being sold together with an accompanying Common Warrant at a combined public offering price of $0.6499, which equals the combined public offering price per Share and accompanying Common Warrant, minus $0.0001.
Pursuant to the Underwriting Agreement, the Company has agreed to pay the Underwriters an underwriting discount equal to 6.0% of the gross proceeds of the Offering. All of the securities in the Offering are being sold by the Company. Pursuant to the Underwriting Agreement, the Company also agreed to reimburse the Representative for certain expenses up to $125,000.
The Underwriting Agreement contains customary representations, warranties and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties. Pursuant to the Underwriting Agreement, and subject to certain exceptions, the Company has agreed not to issue or sell any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock for a period beginning on the date of the Underwriting Agreement and ending 60 days following the closing of the Offering, and not to effect or enter into any variable rate transactions for a period beginning on the date of the Underwriting Agreement and ending six months following the closing of the Offering, in each case without the prior written consent of the Representative. In addition, the Company’s executive officers and directors have agreed, subject to certain exceptions, not to sell or transfer any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock for a period of 60 days from the date of the Underwriting Agreement without the prior written consent of the Representative.
The Company also granted the Representative a 30-day option to purchase up to 8,653,846 additional shares of Common Stock and/or Pre-Funded Warrants to purchase up to 8,653,846 shares of Common Stock and/or Common Warrants to purchase up to 6,490,384 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) (or any combination thereof) at the applicable public offering price minus underwriting discounts and commissions, representing 15% of the total number of shares of Common Stock, Pre-Funded Warrants and Common Warrants sold in the Offering, solely to cover over-allotment, if any.
Each Pre-Funded Warrant has an exercise price of $0.0001 per share of Common Stock, is immediately exercisable upon issuance and may be exercised at any time until exercised in full. Each Common Warrant has an exercise price of $0.65 per share of Common Stock, is immediately exercisable upon issuance, will expire one year from the date of issuance and may be exercised, at the holder’s election, for Pre-Funded Warrants in lieu of shares of Common Stock. A holder may not exercise any portion of its Warrants to the extent that the holder, together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding Common Stock immediately after exercise.
The Common Warrants will be issued pursuant to a warrant agency agreement, dated as of November 12, 2026 (the “Warrant Agency Agreement”), by and between the Company and Securities Transfer Corporation, as warrant agent.
The Company estimates that the gross proceeds of the Offering will be approximately $37.5 million (or approximately $43.1 million if the Representative exercises its option to purchase additional securities in full), prior to deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Warrants. The Company intends to use the net proceeds from the Offering for the Company’s operations, including, but not limited to, research and development, sales and marketing, working capital and other general corporate purposes.
The closing of the Offering is expected to occur on or about November 16, 2026, subject to the satisfaction or waiver of customary closing conditions.
The Offering is being made pursuant to the Company’s effective shelf registration statement on Form S-3 (No. 333-286309), filed with the Securities and Exchange Commission (“SEC”) on April 1, 2025, which became effective on April 10, 2025, and the base prospectus included therein (the “Registration Statement”), as supplemented by preliminary prospectus supplement, dated November 12, 2026, which was filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), and a final prospectus supplement, dated November 13, 2026, relating to and describing the terms of the Offering will be filed with the SEC pursuant to Rule 424(b) under the Securities Act on November 16, 2026.
The Underwriting Agreement, the form of Pre-Funded Warrant, the form of Common Warrant and the Warrant Agency Agreement are filed as Exhibits 1.1, 4.1, 4.2 and 4.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The foregoing descriptions of the terms of the Underwriting Agreement, the Pre-Funded Warrants, the Common Warrants and the Warrant Agency Agreement are qualified in their entirety by reference to such exhibits.
A copy of the opinion, including the related consent, of Greenberg Traurig, P.A. relating to the legality of the issuance and sale of the securities in the Offering is filed as Exhibit 5.1 hereto.
Item 8.01 Other Events.
On November 13, 2026, the Company issued a press release to announce the pricing of the Offering (the “Pricing Press Release”). A copy of the Pricing Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Forward Looking Statements
This Current Report on Form 8-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example, this Current Report on Form 8-K states that the Offering is expected to close on or about November 16, 2026. In fact, the closing of the Offering is subject to various conditions and contingencies as are customary in underwritten public offerings in the United States. If these conditions are not satisfied or the specified contingencies do not occur, this Offering may not close. In addition, forward looking statements in this Current Report on Form 8-K also include the intended use of proceeds from the Offering. For this reason, among others, you should not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this Current Report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |
| 1.1 | Underwriting Agreement, dated November 13, 2026, by and between InspireMD, Inc. and Lake Street Capital Markets, LLC, as representative of the several underwriters named therein | |
| 4.1 | Form of Pre-Funded Warrant to Purchase Common Stock | |
| 4.2 | Form of Series L Warrant to Purchase Common Stock | |
| 4.3 | Warrant Agency Agreement, dated November 12, 2026, by and between InspireMD, Inc. and Securities Transfer Corporation | |
| 5.1 | Opinion of Greenberg Traurig, P.A. | |
| 23.1 | Consent of Greenberg Traurig, P.A. (included in Exhibit 5.1) | |
| 99.1 | Pricing Press Release, dated November 13, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INSPIREMD, INC. | ||
| Date: November 16, 2026 | By: | /s/ Marvin Slosman |
| Name: | Marvin Slosman | |
| Title: | Chief Executive Officer | |